NBPNovaBridge Biosciences
- Market cap
- $158.92M
- as of 2026-10-23
- Latest close
- $1.37
- as of 2026-10-23
- Sector
- Healthcare
- as of 2026-10-24
- Industry
- Biotechnology
- as of 2026-10-24
Cluster
No cluster in the last 90 days under the default rule (14d · ≥2 insiders · all roles).
Form 4 historysince 2026-04-28
| Insider | Traded | Filed | Type | Shares | Price | Value | Owned after | 10b5-1 plan | Filing |
|---|---|---|---|---|---|---|---|---|---|
| Woo Ian Ying | Oct 15 | Oct 19 | M | 13,271 | not reported | not reported | 13,271 | No | Form 4 |
| Woo Ian Ying | Oct 15 | Oct 19 | M · derivative | 5,770 | $0.00 | $0 | 11,540 | No | Form 4 |
| Dennis Phillip AndrewChief Medical Officer | Sep 18 | Sep 21 | S | 8,209 | $0.71 | Sale −$5,828 | 173,427 | No | Form 4 |
| Dennis Phillip AndrewChief Medical Officer | Sep 17 | Sep 21 | M | 23,695 | not reported | not reported | 181,636 | No | Form 4 |
| Dennis Phillip AndrewChief Medical Officer | Sep 17 | Sep 21 | M · derivative | 10,302 | $0.00 | $0 | 72,120 | No | Form 4 |
| Cao Sean WuxiongChief Bus. Development Officer | Sep 9 | Sep 11 | S | 107,978 | $0.74 | Sale −$79,904 | 266,467 | No | Form 4 |
| Cao Sean WuxiongChief Bus. Development Officer | Sep 3 | Sep 8 | M | 235,136 | not reported | not reported | 270,209 | No | Form 4 |
| Cao Sean WuxiongChief Bus. Development Officer | Sep 3 | Sep 8 | M | 104,236 | not reported | not reported | 374,445 | No | Form 4 |
| Cao Sean WuxiongChief Bus. Development Officer | Sep 3 | Sep 8 | M · derivative | 102,233 | $0.00 | $0 | 306,700 | No | Form 4 |
| Cao Sean WuxiongChief Bus. Development Officer | Sep 3 | Sep 8 | M · derivative | 45,320 | $0.00 | $0 | 135,960 | No | Form 4 |
| Xu Cong ClaireEVP, Clinical Development | Aug 31 | Sep 1 | S | 3,282 | $0.79 | Sale −$2,593 | 304,201 | No | Form 4 |
| Xu Cong ClaireEVP, Clinical Development | Aug 30 | Sep 1 | M | 9,382 | not reported | not reported | 307,483 | No | Form 4 |
| Xu Cong ClaireEVP, Clinical Development | Aug 30 | Sep 1 | M · derivative | 4,079 | $0.00 | $0 | 28,558 | No | Form 4 |
| Lenz Robert A. | Aug 22 | Aug 25 | M | 17,218 | not reported | not reported | 17,218 | No | Form 4 |
| Lenz Robert A. | Aug 22 | Aug 25 | M · derivative | 7,486 | $0.00 | $0 | 14,974 | No | Form 4 |
| Lin Liwei LorraineGeneral Counsel | Jul 8 | Jul 10 | A · derivative | 254,780 | $1.93 | $491,725 | 254,780 | No | Form 4 |
| Hagler Mark ArnoldChief Commercial Officer | Jul 8 | Jul 10 | A · derivative | 949,050 | $1.93 | $1,831,667 | 949,050 | No | Form 4 |
| Gupta SrishtiChief Executive Officer | Jul 6 | Jul 8 | A · derivative | 3,000,000 | $2.01 | $6,030,000 | 3,000,000 | No | Form 4 |
| Xu Cong ClaireSVP, Clinical Development | Jul 6 | Jul 7 | S | 4,485 | $0.89 | Sale −$3,992 | 298,101 | No | Form 4 |
| Xu Cong ClaireSVP, Clinical Development | Jul 4 | Jul 7 | M | 12,432 | not reported | not reported | 302,586 | No | Form 4 |
| Xu Cong ClaireSVP, Clinical Development | Jul 4 | Jul 7 | M · derivative | 5,405 | $0.00 | $0 | not reported | No | Form 4 |
| Fu Wei | Jun 29 | Jun 30 | A · derivative | 725,140 | $2.45 | $1,776,593 | 725,140 | No | Form 4 |
| Fu Wei | Jun 29 | Jun 30 | A · derivative | 1,087,720 | $2.45 | $2,664,914 | 1,087,720 | No | Form 4 |
| Fu Wei | Jun 29 | Jun 30 | A · derivative | 1,087,720 | $2.45 | $2,664,914 | 1,087,720 | No | Form 4 |
| Fu Wei | Jun 29 | Jun 30 | A · derivative | 1,010,100 | $0.00 | $0 | 1,010,100 | No | Form 4 |
| Cao Sean WuxiongChief Bus. Development Officer | Jun 22 | Jun 24 | A · derivative | 181,280 | $0.00 | $0 | 181,280 | No | Form 4 |
| Cao Sean WuxiongChief Bus. Development Officer | Jun 22 | Jun 24 | A · derivative | 181,290 | $1.53 | $277,374 | 181,290 | No | Form 4 |
| Dennis Phillip AndrewChief Medical Officer | Jun 18 | Jun 22 | S | 8,494 | $0.66 | Sale −$5,606 | 157,941 | No | Form 4 |
| Dennis Phillip AndrewChief Medical Officer | Jun 17 | Jun 22 | M | 23,695 | not reported | not reported | 166,435 | No | Form 4 |
| Dennis Phillip AndrewChief Medical Officer | Jun 17 | Jun 22 | M · derivative | 10,302 | $0.00 | $0 | 82,422 | No | Form 4 |
| Xu Cong ClaireSVP, Clinical Development | Jun 1 | Jun 2 | S | 3,494 | $3.94 | Sale −$13,766 | 290,154 | No | Form 4 |
| Xu Cong ClaireSVP, Clinical Development | May 30 | Jun 2 | M | 9,382 | not reported | not reported | 293,648 | No | Form 4 |
| Xu Cong ClaireSVP, Clinical Development | May 30 | Jun 2 | M · derivative | 4,079 | $0.00 | $0 | 32,637 | No | Form 4 |
| Cao Sean WuxiongSee Remarks | May 14 | May 18 | S | 21,399 | $1.99 | Sale −$42,584 | 35,073 | No | Form 4 |
| Hagler Mark ArnoldSee Remarks | Apr 24 | Apr 28 | P | 230,000 | $2.51 | Purchase +$577,300 | 230,000 | No | Form 4 |